A little more than a week later, researchers who traveled to India to work on the clinical trial received good news that the phase 1 clinical trial had been a great success. Seventy-three of the 80 patients who participated in the clinical trial had very good values, and the new drug had achieved the expected results.

This made the whole institute very happy, after the first phase could achieve such an effect, things were basically stable, and the remaining second and third phases were just an increase in the number of people. It's also a sign that the prize money is beckoning to them.

Si Mingyu and Li Zhenyuan, who heard the news, both felt normal. Originally, this was a matter of nine out of ten, and after more than three years of careful improvement, it is reasonable for the first phase of clinical trials to achieve such results.

This good news was also spread by several European and American patients who accompanied him.

There are thousands of rare diseases, but there is a big gap in the number of patients, some tens of thousands of people in the world, some more than 100,000 people in the world, as long as they do not exceed the official number standard, they are called rare diseases. The new drug researched by Li Zhenyuan is aimed at one of the diseases with a relatively large number of patients.

Of course, other pharmaceutical companies are also willing to choose rare diseases with a large number of people to develop first, after all, the more consumers will buy at that time. But the research and development of new drugs does not mean that you can produce results if you invest money, so at this time, it is necessary to choose the research and development with a high probability of success, after all, once it fails, there is nothing.

In some countries, patients form mutual aid organizations to encourage and help each other.

After getting the news that the new drug was starting clinical trials, some people in mutual aid organizations followed in order to get first-hand information, after all, it is impossible to overstate how to care about things that can save their lives.

These people are not ordinary people, they all have such and such relationships, so it is difficult for the person in charge of clinical trials to stop them. Besides, there is nothing to stop, and people don't make trouble, they just want to know the progress every day.

Regardless, this exciting news is an inspiration to all.

Everyone knows that drugs for rare diseases are very expensive, but no matter how expensive the medicine is, there is always a price, and if there is no medicine, then even the rich have money and nowhere to spend.

When it comes to the rich, there really must be those who are sick and take out billions or even billions of dollars for pharmaceutical companies to research and treat their own drugs. But it's still the same sentence, it's not that you have money to get results, and it's normal for people to run out if the medicine is not researched.

This good news made some people who wanted to wait until the second phase of the clinical trial no longer hesitate to leave for India immediately.

Indians can participate in phase II clinical trials, and so can they, and some people's conditions can't be delayed, after all, the earlier any disease is treated, the better.

If it is the same success rate as before, they will definitely not dare to take this risk, even if they do not die on the spot, they will fall into serious sequelae, and life is better than death. But now the success rate of more than 90 percent without sequelae is worth the fight, and the risk of 10 percent to save one's life is not worth mentioning at all.

However, this clinical trial is not something that you can participate in if you want to participate in a clinical trial.

Some people will wonder, why can't I send it to your door to be a guinea pig?

No way.

Because it doesn't matter if the Indians have an accident in the clinical trial, as long as they lose money, they won't have to worry about it, and they won't lose much money. But once you Europeans and Americans have an accident, in addition to paying a lot of compensation, they may also be criticized by the media.

Those extremist human rights organizations or Bai Zuo, who is very sick, whether they are voluntary or not, no matter what happened and what your purpose is, just ask you if you are dead? As long as you die, it's your responsibility.

I can't get into trouble with a medical research institute, no.

So there is a strange phenomenon, these European and American patients try their best to participate in clinical trials.

Patients who participate in clinical trials do not charge or undercharge for treatment, and some even pay money. In the face of disease, there are no noble or low, and among these patients, there are naturally rich and ordinary people. There are wealthy people who can't wait for new drugs to be officially launched, and some are ordinary people who can't afford to buy new drugs when they know they are on the market.

And it's not good for you to find the person in charge of clinical trials here, he said that it is not a big boss to nod, after all, he can't afford to pay this responsibility once something happens.

And even if the rich man takes money and asks him to arrange it for you privately, how can so many people turn a blind eye to it. Not to mention that you can buy everyone, if that were the case, there would be no such thing as "trade secrets" in the world.

So the matter was reported to Robert, the head of the branch of the Fifty States Federal Medical Research Institute, and he reported it to Li Zhenyuan.

In the end, Si Mingyu organized a video conference for the three of them.

"Mr. Robert, how do you solve this kind of problem?"

"It depends on how the pharmaceutical company chooses, as long as the people participating in the clinical trial sign detailed legal documents, and in the end, even if they can't win the lawsuit in their home country, then it's no problem. Those white-left fools are everywhere, and no matter what they do, they will jump out and point fingers. "Robert is very experienced in these things." If you don't want to go through the hassle, turn down those patients. ”

"What do those neuropaths have to do with me? Since they voluntarily participate in clinical trials, then we will strictly follow the regulations, and life and death are fateful and rich. "How could Si Mingyu care about the thoughts of a group of foreign madmen.

"Boss, then I know what to do. But I also have a suggestion that for the wealthy, we can provide services at different levels, and the more money you pay, the better you can get, and even involve their personal doctors. Of course, it is the part that does not divulge company secrets, such as daily physical examinations. This is not uncommon on our side. Robert suggested.

"That's a good idea, just do as you say, and take a certain percentage of these extra income as extra bonuses for everyone, but you must strictly follow the prescribed process." Since everyone does it privately, they don't have any scruples.

"Thank you boss!" Robert was overjoyed.

Allowing the rich to spend extra money is a good thing for both parties, the rich have increased the success rate of treatment, the pharmaceutical companies get the money, and everyone has a bright future.

Moreover, the boss also promised additional bonuses. Although this is the second time Robert has met his boss, judging from the past funding for the institute and the treatment of employees, the boss is by no means a stingy person.

For those of them in the Fifty States Federation, as long as the money is enough, they are the hardest working people. They don't work less overtime and don't get less overtime pay, so Robert takes it for granted that new drugs can be developed in advance.

The rest of the matter will be done according to the outcome of this deliberation.